Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
67.00
Ask:
70.00
Spread: 3.00 (4.478%)
Market Cap: £60.33m
CLX Live PriceLast checked at - London Stock Exchange

Intraday Calnex Solutio. Share Chart

AGM Statement

19 Aug 2021 07:00

RNS Number : 0241J
Calnex Solutions PLC
19 August 2021
 

19 August 2021

 

Calnex Solutions plc

("Calnex", the "Company" or the "Group")

 

AGM Statement

Calnex Solutions plc, an established provider of test and measurement solutions for the global telecommunications sector, is pleased to provide an update on trading ahead of its Annual General Meeting taking place at 9am today.

 

Calnex has continued to achieve strong trading and good order levels in the first quarter of FY22, in line with the Board's expectations. Of note in the first few months of the year has been a positive response to the Group's enhancements to its Lab Sync platform, Paragon-Neo, with customers placing encouraging levels of pre-orders ahead of launch later in the year. This new functionality will support testing on the very high speed 400G interface and the new PAM4 interface format. This is a key technology development which is expected to be widely adopted, as organisations upgrade their network infrastructure to cope with the increasing amount of data as a result of the increase in cloud computing and evolution to 5G. Additional recent product developments include the enhancement of our Field Sync platform with, what the Board believes is, the unique ability to test 5G Networks alongside the 3G and 4G support already available, increasing the attractiveness of the platform as telecoms operators look to maintaining their new 5G networks. Whilst cognisant of the uncertainty in the wider industry over the ongoing global semiconductor shortage, the Group has not experienced any negative impact on the ability to manufacture and ship product to date, and the Board continues to monitor the situation closely.

 

The Company was also pleased to receive a Gold standard accreditation from Investors in People, reflecting recognition of Calnex as an organisation with the very best in people management excellence.

 

The strength of trading and positive evolutionary trends affecting the telecoms sector described above provide the Board with continued confidence in Calnex's ability to deliver on its growth strategy and a positive outcome to the year in line with current market expectations.

 

For more information, please contact:

 

Calnex Solutions plc

Via Alma PR

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

 

 

 

Cenkos Securities plc - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

 

 

 

Alma PR

+ 44(0) 20 3405 0213

Caroline Forde, Harriet Jackson, Joe Pederzolli

 

 

 

Overview of Calnex

 

Calnex designs, produces and markets test instrumentation and solutions for network synchronization and network emulation, enabling its customers to validate the performance of the critical infrastructure associated with telecoms networks. To date, Calnex has secured and delivered orders to over 600 customer sites in 68 countries across the world. Customers include BT, China Mobile, NTT, Ericsson, Nokia, Intel, Qualcomm, IBM and Facebook.

 

Founded in 2006, Calnex is headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland and California in the US, supported by sales teams in China and India. Calnex has a global network of partners, providing a worldwide distribution capability. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMSFWSAAEFSEFA
Date   Source Headline
4th May 20237:00 amRNSNotice of Results and Investor Presentation
14th Apr 20236:03 pmRNSPDMR Dealings
14th Apr 20233:24 pmRNSDirector Dealing
15th Mar 20231:15 pmRNSDirector Dealings
14th Mar 20234:00 pmRNSPDMR Dealings
7th Mar 20239:05 amRNSSecond Price Monitoring Extn
7th Mar 20239:00 amRNSPrice Monitoring Extension
7th Mar 20237:00 amRNSTrading Update
15th Feb 202310:59 amRNSPDMR Dealings
19th Jan 20239:56 amRNSPDMR Dealings
17th Jan 20239:56 amRNSDirector / PDMR Dealings
17th Jan 20239:52 amRNSHolding(s) in Company
17th Jan 20237:00 amRNSBoard Changes
13th Jan 20234:00 pmRNSDirector/PDMR Dealing
13th Dec 20222:15 pmRNSDirector / PDMR Dealings
22nd Nov 20227:00 amRNSInterim Results
21st Nov 20225:43 pmRNSDirector / PDMR Dealings
27th Oct 20227:00 amRNSNotice of Results and Investor Presentation
14th Oct 20223:53 pmRNSDirector/PDMR Shareholding
12th Oct 20221:29 pmRNSDirector / PDMR Dealings
15th Sep 20227:30 amRNSDirector/PDMR Dealing
17th Aug 20225:26 pmRNSResult of AGM
17th Aug 20227:00 amRNSAGM Statement
15th Aug 202210:26 amRNSDirector / PDMR Dealings
26th Jul 20223:33 pmRNSDirector / PDMR Shareholding
18th Jul 20227:00 amRNSNotice of AGM
14th Jul 20225:49 pmRNSDirector/PDMR Dealings
8th Jul 20226:01 pmRNSDirector / PDMR dealings
15th Jun 20227:00 amRNSExercise of Options
14th Jun 20227:00 amRNSBoard Update
6th Jun 20221:30 pmRNSDirector Dealing
24th May 20227:00 amRNSFY22 Final Results
6th May 20227:00 amRNSNotice of Investor Presentation
26th Apr 20229:13 amRNSAward of Options
22nd Apr 202210:50 amRNSHolding(s) in Company
21st Apr 20223:37 pmRNSPDMR Dealing
21st Apr 20227:00 amRNSCalnex receives two Queen’s awards for Enterprise
12th Apr 20227:00 amRNSAcquisition of iTrinegy and Update on Trading
1st Mar 20227:00 amRNSTrading Update
25th Jan 202210:00 amRNSDirector Dealing
11th Jan 20227:00 amRNSBoard Appointments
29th Nov 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20219:55 amRNSHolding(s) in Company
23rd Nov 20214:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20214:35 pmRNSPrice Monitoring Extension
23rd Nov 20212:06 pmRNSSecond Price Monitoring Extn
23rd Nov 20212:00 pmRNSPrice Monitoring Extension
23rd Nov 20217:00 amRNSInterim Results
10th Nov 20217:00 amRNSNotice of Results and Investor Presentation
3rd Nov 202111:03 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.